Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas

Journal Article

46 previously untreated patients with advanced aggressive non-Hodgkin's (34 poorly differentiated and mixed diffuse, 8 histiocytic and 4 undifferentiated) were treated with a 3 phase combined modality program employing cyclophosphamide (C), hydroxyl-daunomycin (H), vincristine (O), prednisone (P), procarbazine (P) [CHOP(P)] combination chemotherapy in an initial induction phase, radiotherapy and nonmarrow toxic chemotherapy as a second consolidation phase, followed by a third phase of CHOP(P) chemotherapy for 4 more cycles. Long-term maintenance therapy was not given. High dose involved field radiation in phase II was limited to volumes encompassing less than 50% of the marrow bearing skeleton. The large majority of patients (82%) had such widespread involvement that this limitation precluded the use of local radiation and were treated instead with a mean of 132 rad of fractionated total body irradiation (TBI). 38 patients (83%) achieved complete remission. 29 (66%) of the 44 patients evaluable for follow-up, and 22 (61%) of the 36 patients receiving TBI, remain alive in complete remission for observation periods of up to 26 months.

Duke Authors

Cited Authors

  • Harrison, DT; Neiman, PE; Sullivan, K; Hafermann, M; Rudolph, RH; Jr, ABE

Published Date

  • 1978

Published In

Volume / Issue

  • 42 / 4

Start / End Page

  • 1697 - 1704

PubMed ID

  • 361208

International Standard Serial Number (ISSN)

  • 0008-543X